Trial
NCT03099499
Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Fox Chase Cancer Center
Collaborators
Oncoceutics, Inc.
Condition
Endometrial Cancer
Intervention
ONC201
Why stopped
Slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-12-24